From: Chromophobe renal cell cancer - review of the literature and potential methods of treating metastatic disease
Agent
No. of patients
Median PFS (months)
Partial Response
Stable Disease
Sunitinib
7
8.9
1
6
Sorafenib
5
27.5
2
3